Croda International Plc Q2 2026 Earnings Recap

Shares rose 10.1% following results that demonstrated accelerating growth in Consumer Care, particularly Beauty Actives, and margin expansion supported by transformation cost savings, confirming confidence in the unchanged full-year outlook.

Key Takeaways

• Constant currency sales increased 5% to GBP 881 million, led by 8% growth in Consumer Care and 7% growth in Pharma Ingredients.
• Beauty Actives sales surged 27% in Q2, benefiting from customer innovation and product launches, driving improved second-quarter performance.
• Adjusted operating profit rose 7% to GBP 156 million, with a 50 basis point margin expansion driven by higher volumes, pricing, mix, and GBP 18 million in transformation cost savings.
• Free cash flow improved to GBP 38 million, with net debt and leverage remaining stable and conservative at 1.4x EBITDA.
• Full-year guidance remains unchanged, with expected organic sales growth of 3% to 6% and margin expansion, supported by a strong pipeline and ongoing transformation.